🏛️ Verified NIH Record • Updated 2025-10-02
An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome (NCT05367960)
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Tetra Discovery Partners
🩺 Plain-English Summary (8th-Grade Level)
This is a 4-year, open-label extension (OLE) study for subjects completing one of two double-blind clinical trials with BPN14770, Study BPN14770-CNS-301 (in adult males) and Study BPN14770-CNS-204 (in adolescent males).
Who can join: Review the eligibility criteria below.
Location: Amnova Clinical Research — Irvine, California
Age range: 9 Years to 45 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (17 Sites)
- Amnova Clinical Research — Irvine, California
- Thompson Autism & Neurodevelopment Center - CHOC — Orange, California
- MIND Institute UC Davis Medical Center — Sacramento, California
- Children's Hospital Colorado — Aurora, Colorado
- University of Miami — Miami, Florida
- Emory University School of Medicine — Atlanta, Georgia
- Rush University Medical Center — Chicago, Illinois
- University of Kansas Medical Center — Kansas City, Kansas
- Kennedy Krieger Institute — Baltimore, Maryland
- Boston Children's Hospital — Boston, Massachusetts
- U Mass — Worcester, Massachusetts
- Icahn School of Medicine at Mount Sinai — New York, New York
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Suburban Research Associates — Media, Pennsylvania
- Clinic for Special Children — Strasburg, Pennsylvania
- Greenwood Genetic Center — Greenville, South Carolina
- University of Utah and Primary Children's Hospital — Salt Lake City, Utah
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Fragile X Syndrome
- Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge — Cincinnati, Ohio
- Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS — Phoenix, Arizona
- Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG- Infant — Cincinnati, Ohio
- Effect of CANnabidiol on Anxiety and GABAergic Function in Individuals With Fragile-X Syndrome — Sherbrooke, Quebec
- Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM) — Phoenix, Arizona
Explore by condition: All Fragile X Syndrome clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.